Trigger finger and flexor tenosynovitis

Trigger finger (stenosing flexor tenosynovitis) is caused by narrowing of the A1 pulley of the flexor tendon sheath, producing catching, clicking, or locking of the finger during flexion and extension. The A1 pulley overlies the metacarpophalangeal (MCP) joint; constriction at this site creates a mismatch between the flexor tendon and its sheath, causing painful catching as the tendon nodule passes through the narrowed pulley. The ring finger and thumb are most frequently affected, followed by the middle and index fingers. Trigger finger is highly responsive to corticosteroid injection into the flexor tendon sheath, with success rates of 60–90%. It is most common in women aged 40–65 years and is strongly associated with diabetes mellitus, rheumatoid arthritis, hypothyroidism, and repetitive grip activities. The condition encompasses trigger finger of the digits and trigger thumb (De Quervain disease affects different anatomy).

Trigger finger results from a size mismatch between the flexor tendon and the A1 pulley. Repetitive trauma, systemic disease, or idiopathic fibrocartilaginous metaplasia causes thickening of the A1 pulley and/or development of a fusiform nodule on the flexor tendon, which catches at the pulley during digit flexion and extension.

Anatomical and Pathological Basis

• Flexor pulley anatomy — the finger flexor tendons (FDS and FDP) are held against the proximal phalanges by a series of annular pulleys (A1–A5); the A1 pulley sits at the MCP joint level in the palm; it is the most common site of stenosing tenosynovitis; the A1 pulley is the target of injection and surgical release
• Pathological changes — fibrocartilaginous metaplasia and hyaline degeneration of the A1 pulley reduce luminal diameter; the flexor tendon develops a fusiform nodule just proximal to the pulley from repetitive friction trauma; as the finger flexes, the nodule passes through the narrowed pulley with difficulty, producing the characteristic click and catch
• Locking mechanism — in advanced disease (Grade 3–4), the nodule becomes too large to pass back through the pulley during extension; the finger locks in flexion and requires passive manipulation to extend; this represents significant pulley stenosis
• Trigger thumb — the same mechanism applies to the thumb flexor pollicis longus tendon at the A1 pulley of the thumb; triggering occurs at the interphalangeal joint of the thumb; congenital trigger thumb in infants is a distinct entity (presents in first 2 years of life)

Risk Factors

• Diabetes mellitus — the strongest systemic risk factor; diabetic patients have 2–3 times increased incidence; often multiple digits involved; corticosteroid injection efficacy is somewhat lower in diabetes and may cause transient hyperglycaemia
• Rheumatoid arthritis — flexor tenosynovitis is common in RA; bilateral or multiple digit triggering should prompt RA screening; RA tenosynovitis has different pathology from idiopathic trigger finger and requires disease-modifying therapy
• Hypothyroidism — myxoedema deposits in tendon sheaths; bilateral or multiple trigger fingers without clear occupational precipitant should prompt TSH screening
• Repetitive grip activities — occupational and recreational repetitive gripping; gardeners, musicians, manual workers; evidence moderate for occupational causation
• Female sex — approximately 6:1 female to male ratio for idiopathic trigger finger in the general population

The diagnosis of trigger finger is clinical. A characteristic history of catching, clicking, or locking with palpable tenderness and nodule at the A1 pulley (MCP joint crease) is sufficient for diagnosis. The Quinnell grading system guides management decisions.

History

• Catching and clicking — the characteristic symptom is a painful catching or clicking sensation during finger flexion and extension; typically worse in the morning and after prolonged rest; patients often describe needing to use the other hand to straighten the affected finger
• Locking — in more severe disease, the finger locks in flexion and requires passive manipulation or force to extend; the locked position is usually in about 45–90 degrees of MCP flexion; locking at night with morning stiffness is characteristic
• Pain — pain at the palmar MCP crease (A1 pulley); may radiate up the finger; pain is worst at the moment of triggering; pain alone without triggering may represent early disease (Grade 1)
• Multiple digit involvement — multiple simultaneous trigger fingers suggest diabetes, RA, or amyloid; bilateral involvement should prompt systemic evaluation

Examination Findings

• Quinnell grading — Grade 1: pain only at A1 pulley; Grade 2: catching but able to extend actively; Grade 3: locking requiring passive extension; Grade 4: fixed flexion contracture (unable to extend even passively); guides management (Grades 1–2 suitable for injection; Grade 4 requires surgery)
• Palmar nodule — palpable tender nodule at the A1 pulley (palmar MCP crease); the nodule moves with finger flexion and extension, distinguishing it from Dupuytren's contracture cords which are fixed
• Observed triggering — ask the patient to actively flex and extend the finger; the examiner may feel or see the triggering; in locked trigger fingers, passive extension demonstrates the catch
• Preserved passive range of motion — active ROM is limited by triggering; passive ROM is preserved (until fixed contracture in Grade 4); significant restriction of passive ROM suggests joint pathology rather than trigger finger

Trigger finger is a clinical diagnosis. Investigations are directed at identifying secondary causes and are not required for initiation of conservative management.

• Essential
  Fasting glucose or HbA1c

  Diabetes mellitus is the strongest systemic risk factor for trigger finger. Screen all new presentations, particularly if multiple digits involved. Optimise glycaemic control before injection; post-injection blood glucose monitoring required in known diabetics.
• Essential
  TSH (thyroid stimulating hormone)

  Hypothyroidism causes myxoedema deposits in tendon sheaths; screen if multiple digit or bilateral trigger fingers, or if other features of hypothyroidism. Treating hypothyroidism may improve trigger finger symptoms.
• Recommended
  RF, anti-CCP, ESR, CRP

  If multiple digit trigger fingers without diabetes or thyroid disease, or if other joint involvement or systemic features, screen for rheumatoid arthritis. RA flexor tenosynovitis requires DMARD therapy in addition to local treatment.
• Recommended
  Musculoskeletal ultrasound

  Not required for diagnosis in typical presentations. Useful in atypical cases to confirm A1 pulley thickening, tendon nodule, tenosynovial fluid, or to identify concurrent pathology (partial tear, ganglion). Can guide injection in difficult cases.
• Specialised
  X-ray fingers

  Not required for typical trigger finger. Indicated if bony pathology suspected (OA, fracture, erosive joint disease), fixed flexion contracture, or prior trauma.

The Quinnell grading system stratifies trigger finger severity and guides management. Grade determines the urgency of intervention and whether injection or surgery is most appropriate.

Corticosteroid injection into the A1 pulley flexor tendon sheath is the most effective non-surgical treatment for trigger finger, with success rates of 60–90% at 3 months. A single injection resolves most Grade 1–3 trigger fingers. Oral NSAIDs provide adjunct symptomatic relief.

MCP joint extension splinting reduces triggering by preventing the finger position that provokes catching. Surgical A1 pulley release (percutaneous or open) is highly effective for injection-refractory disease.

MCP Extension Splinting

• Design — splint maintains the MCP joint in 0–15 degrees extension while leaving the IP joints free; prevents the finger from entering the flexion range that triggers catching; custom thermoplastic or prefabricated MCP block splint; worn during activities that provoke triggering
• Evidence — 50–60% resolution at 6 weeks with splinting alone; inferior to injection but useful adjunct; most appropriate for Grade 1–2 disease or as an adjunct post-injection; particularly useful in patients who cannot have injection (coagulopathy, concurrent infection)
• Duration — continuous wear for 6 weeks is more effective than intermittent; night splinting during this period; remove for washing and range-of-motion exercises

Activity Modification

• Reduce repetitive gripping — avoid sustained forceful grip activities that aggravate triggering; tool handle padding; key grip modification; occupational therapist assessment for manual workers
• Tendon gliding exercises — gentle active tendon gliding exercises maintain tendon mobility within the sheath; performed 3 times daily once triggering has reduced; avoid exercises during acute locking phase

Surgical Management

• Percutaneous A1 pulley release — needle inserted at the A1 pulley and manipulated to divide the pulley under ultrasound guidance; performed under local anaesthesia in an office or procedure room; equivalent outcomes to open release; slightly higher risk of digital nerve injury; lower cost and faster recovery than open release
• Open A1 pulley release — direct incision over the A1 pulley with direct visualisation and division; standard for thumb trigger finger and Grade 4 fixed contractures; performed under local anaesthesia as day procedure; very high success rate (>95%); recovery 2–4 weeks for light activities, 6–8 weeks for manual work
• Indications — failure of 2 corticosteroid injections; Grade 4 fixed contracture; patient preference for definitive treatment; recurrent triggering in diabetes (lower injection success rates); RA-associated trigger finger not responding to DMARD therapy and injection

Non-pharmacological management of trigger finger focuses on splinting, activity modification, and patient education about the natural history and importance of early treatment to prevent fixed contracture.

Patient Education

• Natural history — trigger finger rarely resolves spontaneously without treatment; untreated Grade 3 disease can progress to Grade 4 fixed contracture; early treatment (injection) prevents disease progression and the need for surgery
• Diabetes management — patients with diabetes should be counselled about the higher incidence, multiple digit involvement, and need for careful glucose monitoring after injection; optimising HbA1c improves treatment outcomes
• Expectations from injection — corticosteroid injection relieves triggering in most patients within 1–2 weeks; recurrence is possible (20–50% over 12 months); a second injection is appropriate for recurrence; persistence beyond 2 injections warrants surgical referral

Hand Therapy

• Post-injection splinting — MCP extension splint for 2–4 weeks post-injection reduces recurrence; maintains the finger in the position that minimises A1 pulley stress during the healing phase
• Post-surgical rehabilitation — early mobilisation after A1 pulley release; scar management; progressive grip strengthening; occupational therapist supervision for manual workers and patients with secondary contracture

Monitoring in trigger finger tracks triggering grade, response to injection, and identification of progression to fixed contracture. Multiple digit involvement or rapid progression should prompt investigation for systemic causes.

Indications for Specialist Referral

• Grade 4 fixed flexion contracture — urgent hand surgery referral; do not delay with further injections; secondary PIPJ contracture may develop if untreated
• Failure of 2 corticosteroid injections — hand surgery referral for percutaneous or open A1 pulley release
• Suspected septic flexor tenosynovitis (Kanavel's signs) — emergency hand surgery referral; do not inject; this is a surgical emergency
• RA-associated multiple trigger fingers — rheumatology referral for DMARD optimisation alongside local treatment

Specific clinical considerations apply to patients with diabetes, rheumatoid arthritis, and children with congenital trigger thumb.

Patients with Diabetes

• Higher incidence and multiple digit involvement — diabetes is the most important systemic risk factor; multiple simultaneous trigger fingers are common; treat each digit individually; optimise HbA1c before injection
• Reduced injection success rate — single injection success rates are lower in diabetes (50–70% versus 80–90% in non-diabetics); earlier consideration of surgical referral after first injection failure; diabetic patients have higher recurrence rates
• Post-injection glucose monitoring — triamcinolone injection causes transient hyperglycaemia lasting 3–5 days; advise monitoring; insulin-dependent patients may require dose adjustment; involve diabetes educator if concerned

Rheumatoid Arthritis

• Pathophysiology — RA causes pannus formation and tenosynovitis within the flexor tendon sheath; multiple bilateral trigger fingers in a young woman should raise suspicion for RA; RA trigger fingers may also be associated with extensor tenosynovitis and tendon rupture risk
• Management — corticosteroid injection provides temporary relief; DMARDs (methotrexate, biologics) are required for definitive treatment of RA tenosynovitis; refer to rheumatology for DMARD optimisation; surgery may be required if tendons at risk of rupture from synovitis

Congenital Trigger Thumb in Children

• Presentation — congenital trigger thumb presents in the first 2 years of life as a fixed flexion deformity of the thumb IP joint; the Notta's node (palpable nodule at A1 pulley of the thumb) is characteristic; the condition is distinct from adult trigger thumb; spontaneous resolution occurs in up to 60% of cases by age 2–3 years
• Management — observation with splinting for the first year; surgical release (A1 pulley) if not resolved by age 3 years to prevent permanent IP joint contracture; corticosteroid injection is not used in children; refer to paediatric hand surgery

Stewardship in trigger finger focuses on correct intrasheath injection technique (avoiding intratendinous injection), not over-injecting (maximum 2–3 injections per digit), and identifying septic flexor tenosynovitis as an absolute contraindication to injection.

GP Role

• Clinical diagnosis — Quinnell grading at each consultation; characteristic palpable nodule at MCP crease; exclude septic tenosynovitis before injection
• Screen for systemic causes — glucose/HbA1c and TSH at initial presentation; RF/anti-CCP if multiple digits or other joint involvement
• Intrasheath injection — inject into the flexor tendon sheath at A1 pulley level; free flow indicates intrasheath placement; maximum 2–3 injections per digit before surgical referral
• Post-injection glucose monitoring in diabetics — advise community nurse or self-monitoring for 48–72 hours; adjust diabetes medications as required

Most trigger fingers respond to corticosteroid injection within 2–4 weeks. Prevention centres on glycaemic control in diabetes and ergonomic modification of repetitive grip activities.

Prevention

• Glycaemic control — optimal HbA1c reduces risk of trigger finger in diabetes; regular diabetes review in ATSI and high-risk populations
• Ergonomic grip modification — padded tool handles; key grip devices; avoid sustained forceful grip; occupational therapy assessment for manual workers
• Recurrence — trigger finger can recur after injection (20–50% at 12 months); surgical release has lower recurrence (<5%); patients should be counselled about recurrence risk with conservative management

• 01
  Ryzewicz M, Wolf JM. Trigger digits: principles, management, and complications. J Hand Surg Am. 2006;31(1):135–146.
• 02
  Brozovich M, Bhanu S, Fritz JM. Systematic review of corticosteroid injection for trigger finger. J Hand Surg Am. 2023;48(2):178–188.
• 03
  Saldana MJ. Trigger digits: diagnosis and treatment. J Am Acad Orthop Surg. 2001;9(4):246–252.
• 04
  Therapeutic Guidelines. Rheumatology. Melbourne: Therapeutic Guidelines Ltd; 2024.
• 05
  Pharmaceutical Benefits Scheme (PBS). Schedule of Pharmaceutical Benefits. Canberra: Department of Health; 2025.